NU-LISINOPRIL TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

LISINOPRIL

Mevcut itibaren:

NU-PHARM INC

ATC kodu:

C09AA03

INN (International Adı):

LISINOPRIL

Doz:

20MG

Farmasötik formu:

TABLET

Kompozisyon:

LISINOPRIL 20MG

Uygulama yolu:

ORAL

Paketteki üniteler:

30/100/500

Reçete türü:

Prescription

Terapötik alanı:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Ürün özeti:

Active ingredient group (AIG) number: 0121550002; AHFS:

Yetkilendirme durumu:

CANCELLED (UNRETURNED ANNUAL)

Yetkilendirme tarihi:

2018-03-28

Ürün özellikleri

1
PRODUCT MONOGRAPH
PR
NU-LISINOPRIL
LISINOPRIL TABLETS USP
5, 10, 20 AND 40 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL STREET, UNITS 1 & 2
October 7, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133152
_ _
1
PRODUCT MONOGRAPH
Pr
NU-LISINOPRIL
Lisinopril Tablets USP
5, 10, 20 and 40 mg
THERAPEUTIC CLASSIFICATION
Angiotensin Converting Enzyme Inhibitor
ACTION AND CLINICAL PHARMACOLOGY
Lisinopril is an ACE inhibitor, which is used in the treatment of
hypertension, congestive heart
failure and following myocardial infarction in hemodynamicaly stable
patients.
Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion of
angiotensin I to the pressor substance, angiotensin II. Inhibition of
ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum K+. In patients treated
with lisinopril and a thiazide
diuretic there was essentially no change in serum potassium (see
PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of NU-
LISINOPRIL is unknown.
2
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system lisinopril
also lowers blood pressure
in patients with low-renin hypertension.
Administration of lisinopril to patients with hypertension results in
a reduction of both supine and
standing blood pressure. Abrupt withdrawal of lisinopril has not been
associated with a rapid
increase in blood pressure. In most patients studied, after oral
administration of an individual
dose of lisinopril, the onset of antihypertensive activity is seen at
one hour with peak reduction of
blood pressure achieved by